Hamraz Mokri, Pieter van Baal, Maureen Rutten-van Mölken
{"title":"心力衰竭的终生医疗保健和长期护理费用:使用荷兰住院患者的行政数据进行估计。","authors":"Hamraz Mokri, Pieter van Baal, Maureen Rutten-van Mölken","doi":"10.1007/s40273-025-01533-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Heart failure (HF) is a complex clinical syndrome associated with high mortality and extensive healthcare use. Using longitudinal data, we aimed to estimate the lifetime healthcare and long-term care (LTC) use and costs of Dutch patients with HF.</p><p><strong>Methods: </strong>We used linked administrative data on mortality, LTC, and healthcare use covering the entire Dutch population for the period 2013-2024. Newly diagnosed patients with HF were defined as patients who were not hospitalized for HF 2 years before their index hospitalization for HF in 2015. Using regression modeling, we estimated hospitalized patients' life expectancy and lifetime healthcare costs as a function of age, sex, comorbidity, and income (all costs were adjusted to 2021 values).</p><p><strong>Results: </strong>We identified 21,011 unique hospitalized patients with HF (mean age 80 years), of whom 86% died during follow-up. Estimated lifetime total healthcare and LTC costs varied between €35,000 and €170,000, depending on patient characteristics. Lifetime LTC costs varied between €9000 and €50,000. While comorbidity affects life expectancy substantially, it did not have a strong impact on lifetime costs. Income level affects costs more than comorbidities, and lower-income groups incur higher lifetime LTC costs.</p><p><strong>Conclusions: </strong>Despite people with lower incomes having shorter lifespans than those with higher incomes, their lifetime LTC costs are higher. However, people with higher incomes have higher hospital costs, partly owing to their longer life expectancy.</p>","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lifetime Healthcare and Long-Term Care Costs of Heart Failure: Estimates Using Administrative Data from Hospitalized Patients in the Netherlands.\",\"authors\":\"Hamraz Mokri, Pieter van Baal, Maureen Rutten-van Mölken\",\"doi\":\"10.1007/s40273-025-01533-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>Heart failure (HF) is a complex clinical syndrome associated with high mortality and extensive healthcare use. Using longitudinal data, we aimed to estimate the lifetime healthcare and long-term care (LTC) use and costs of Dutch patients with HF.</p><p><strong>Methods: </strong>We used linked administrative data on mortality, LTC, and healthcare use covering the entire Dutch population for the period 2013-2024. Newly diagnosed patients with HF were defined as patients who were not hospitalized for HF 2 years before their index hospitalization for HF in 2015. Using regression modeling, we estimated hospitalized patients' life expectancy and lifetime healthcare costs as a function of age, sex, comorbidity, and income (all costs were adjusted to 2021 values).</p><p><strong>Results: </strong>We identified 21,011 unique hospitalized patients with HF (mean age 80 years), of whom 86% died during follow-up. Estimated lifetime total healthcare and LTC costs varied between €35,000 and €170,000, depending on patient characteristics. Lifetime LTC costs varied between €9000 and €50,000. While comorbidity affects life expectancy substantially, it did not have a strong impact on lifetime costs. Income level affects costs more than comorbidities, and lower-income groups incur higher lifetime LTC costs.</p><p><strong>Conclusions: </strong>Despite people with lower incomes having shorter lifespans than those with higher incomes, their lifetime LTC costs are higher. However, people with higher incomes have higher hospital costs, partly owing to their longer life expectancy.</p>\",\"PeriodicalId\":19807,\"journal\":{\"name\":\"PharmacoEconomics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmacoEconomics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40273-025-01533-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ECONOMICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40273-025-01533-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
Lifetime Healthcare and Long-Term Care Costs of Heart Failure: Estimates Using Administrative Data from Hospitalized Patients in the Netherlands.
Background and objective: Heart failure (HF) is a complex clinical syndrome associated with high mortality and extensive healthcare use. Using longitudinal data, we aimed to estimate the lifetime healthcare and long-term care (LTC) use and costs of Dutch patients with HF.
Methods: We used linked administrative data on mortality, LTC, and healthcare use covering the entire Dutch population for the period 2013-2024. Newly diagnosed patients with HF were defined as patients who were not hospitalized for HF 2 years before their index hospitalization for HF in 2015. Using regression modeling, we estimated hospitalized patients' life expectancy and lifetime healthcare costs as a function of age, sex, comorbidity, and income (all costs were adjusted to 2021 values).
Results: We identified 21,011 unique hospitalized patients with HF (mean age 80 years), of whom 86% died during follow-up. Estimated lifetime total healthcare and LTC costs varied between €35,000 and €170,000, depending on patient characteristics. Lifetime LTC costs varied between €9000 and €50,000. While comorbidity affects life expectancy substantially, it did not have a strong impact on lifetime costs. Income level affects costs more than comorbidities, and lower-income groups incur higher lifetime LTC costs.
Conclusions: Despite people with lower incomes having shorter lifespans than those with higher incomes, their lifetime LTC costs are higher. However, people with higher incomes have higher hospital costs, partly owing to their longer life expectancy.
期刊介绍:
PharmacoEconomics is the benchmark journal for peer-reviewed, authoritative and practical articles on the application of pharmacoeconomics and quality-of-life assessment to optimum drug therapy and health outcomes. An invaluable source of applied pharmacoeconomic original research and educational material for the healthcare decision maker.
PharmacoEconomics is dedicated to the clear communication of complex pharmacoeconomic issues related to patient care and drug utilization.
PharmacoEconomics offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article.